BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Halperin DM, Shen C, Dasari A, Xu Y, Chu Y, Zhou S, Shih YT, Yao JC. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. Lancet Oncol. 2017;18:525-534. [PMID: 28238592 DOI: 10.1016/s1470-2045(17)30110-9] [Cited by in Crossref: 132] [Cited by in F6Publishing: 68] [Article Influence: 33.0] [Reference Citation Analysis]
Number Citing Articles
1 Kayano D, Kinuya S. Current Consensus on I-131 MIBG Therapy. Nucl Med Mol Imaging 2018;52:254-65. [PMID: 30100938 DOI: 10.1007/s13139-018-0523-z] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 7.7] [Reference Citation Analysis]
2 Byun S, Affolter KE, Snow AK, Curtin K, Cannon AR, Cannon-Albright LA, Thota R, Neklason DW. Differential methylation of G-protein coupled receptor signaling genes in gastrointestinal neuroendocrine tumors. Sci Rep 2021;11:12303. [PMID: 34112938 DOI: 10.1038/s41598-021-91934-5] [Reference Citation Analysis]
3 Dillon JS. Workup of Gastroenteropancreatic Neuroendocrine Tumors. Surg Oncol Clin N Am 2020;29:165-83. [PMID: 32151354 DOI: 10.1016/j.soc.2019.10.002] [Reference Citation Analysis]
4 Fanciulli G, Ruggeri RM, Grossrubatscher E, Calzo FL, Wood TD, Faggiano A, Isidori A, Colao A; NIKE. Serotonin pathway in carcinoid syndrome: Clinical, diagnostic, prognostic and therapeutic implications. Rev Endocr Metab Disord 2020;21:599-612. [PMID: 32152781 DOI: 10.1007/s11154-020-09547-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
5 Liu P, Zhang X, Shang Y, Lu L, Cao F, Sun M, Tang Z, Vollmar B, Gong P. Lymph node ratio, but not the total number of examined lymph nodes or lymph node metastasis, is a predictor of overall survival for pancreatic neuroendocrine neoplasms after surgical resection.Oncotarget. 2017;8:89245-89255. [PMID: 29179516 DOI: 10.18632/oncotarget.19184] [Cited by in Crossref: 7] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
6 Halperin DM, Huynh L, Beaumont JL, Cai B, Totev T, Bhak RH, Duh MS, Neary MP, Cella D. Impact of carcinoid syndrome symptoms and long-term use of somatostatin analogs on quality of life in patients with carcinoid syndrome: A survey study. Medicine (Baltimore) 2018;97:e13390. [PMID: 30461659 DOI: 10.1097/MD.0000000000013390] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
7 Kiesewetter B, Duan H, Lamm W, Haug A, Riss P, Selberherr A, Scheuba C, Raderer M. Oral Ondansetron Offers Effective Antidiarrheal Activity for Carcinoid Syndrome Refractory to Somatostatin Analogs. Oncologist. 2019;24:255-258. [PMID: 30171068 DOI: 10.1634/theoncologist.2018-0191] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
8 Arasaradnam RP, Brown S, Forbes A, Fox MR, Hungin P, Kelman L, Major G, O'Connor M, Sanders DS, Sinha R, Smith SC, Thomas P, Walters JRF. Guidelines for the investigation of chronic diarrhea in adults: British Society of Gastroenterology, 3rd edition. Gut. 2018;67:1380-1399. [PMID: 29653941 DOI: 10.1136/gutjnl-2017-315909] [Cited by in Crossref: 91] [Cited by in F6Publishing: 70] [Article Influence: 30.3] [Reference Citation Analysis]
9 Yao JC, Oh DY, Qian J, Park YS, Herbst F, Ridolfi A, Izquierdo M, Ito T, Jia L, Komoto I, Sriuranpong V, Shimada Y. Everolimus for the treatment of advanced gastrointestinal or lung nonfunctional neuroendocrine tumors in East Asian patients: a subgroup analysis of the RADIANT-4 study. Onco Targets Ther 2019;12:1717-28. [PMID: 30881026 DOI: 10.2147/OTT.S182259] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
10 Shen C, Dasari A, Gu D, Chu Y, Zhou S, Xu Y, Halperin D, Fu S, Yao JC, Shih YT. Costs of Cancer Care for Elderly Patients with Neuroendocrine Tumors. Pharmacoeconomics 2018;36:1005-13. [PMID: 29682693 DOI: 10.1007/s40273-018-0656-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
11 Yanagisawa A, Hirano S, Shimizu S, Hiroishi T, Shikano K, Hayama N, Fujita T, Amano H, Nakamura M, Nakamura S, Tabeta H. Metastatic Recurrence of Typical Pulmonary Carcinoid Accompanied by Carcinoid Syndrome, Successfully Treated with Octreotide LAR. Case Rep Oncol Med 2017;2017:1564819. [PMID: 29445555 DOI: 10.1155/2017/1564819] [Reference Citation Analysis]
12 Pedraza-Arévalo S, Gahete MD, Alors-Pérez E, Luque RM, Castaño JP. Multilayered heterogeneity as an intrinsic hallmark of neuroendocrine tumors. Rev Endocr Metab Disord 2018;19:179-92. [PMID: 30293213 DOI: 10.1007/s11154-018-9465-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
13 Dasari A, Joish VN, Perez-Olle R, Dharba S, Balaji K, Halperin DM. Direct costs of carcinoid syndrome diarrhea among adults in the United States. World J Gastroenterol 2019; 25(47): 6857-6865 [PMID: 31885426 DOI: 10.3748/wjg.v25.i47.6857] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Goksu SY, Ozer M, Beg MS, Sanford NN, Ahn C, Fangman BD, Goksu BB, Verma U, Sanjeevaiah A, Hsiehchen D, Jones AL, Kainthla R, Kazmi SM. Racial/Ethnic Disparities and Survival Characteristics in Non-Pancreatic Gastrointestinal Tract Neuroendocrine Tumors. Cancers (Basel) 2020;12:E2990. [PMID: 33076486 DOI: 10.3390/cancers12102990] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Kulke MH, Benson AB, Dasari A, Huynh L, Cai B, Totev T, Roesner N, Duh MS, Neary MP, Maurer VE, Shih BE, Dagohoy CG, Chan J, Bergsland EK. Real-World Treatment Patterns and Clinical Outcomes in Advanced Gastrointestinal Neuroendocrine Tumors (GI NET): A Multicenter Retrospective Chart Review Study. Oncologist 2019;24:1056-65. [PMID: 30606883 DOI: 10.1634/theoncologist.2018-0519] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Imperiale A, Poncet G, Addeo P, Ruhland E, Roche C, Battini S, Cicek AE, Chenard MP, Hervieu V, Goichot B, Bachellier P, Walter T, Namer IJ. Metabolomics of Small Intestine Neuroendocrine Tumors and Related Hepatic Metastases. Metabolites. 2019;9. [PMID: 31835679 DOI: 10.3390/metabo9120300] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
17 Adams JR, Ray D, Willmon R, Pulgar S, Dasari A. Living With Neuroendocrine Tumors: Assessment of Quality of Life Through a Mobile Application. JCO Clin Cancer Inform 2019;3:1-10. [PMID: 31283354 DOI: 10.1200/CCI.19.00025] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
18 Alwan H, La Rosa S, Andreas Kopp P, Germann S, Maspoli-Conconi M, Sempoux C, Bulliard JL. Incidence trends of lung and gastroenteropancreatic neuroendocrine neoplasms in Switzerland. Cancer Med 2020;9:9454-61. [PMID: 33078908 DOI: 10.1002/cam4.3524] [Reference Citation Analysis]
19 Herrera-Martínez AD, Hofland J, Hofland LJ, Brabander T, Eskens FALM, Gálvez Moreno MA, Luque RM, Castaño JP, de Herder WW, Feelders RA. Targeted Systemic Treatment of Neuroendocrine Tumors: Current Options and Future Perspectives. Drugs 2019;79:21-42. [PMID: 30560479 DOI: 10.1007/s40265-018-1033-0] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 11.0] [Reference Citation Analysis]
20 Zhong Q, Chen QY, Xie JW, Wang JB, Lin JX, Lu J, Cao LL, Lin M, Tu RH, Huang ZN, Lin JL, Li P, Zheng CH, Huang CM. Incidence trend and conditional survival estimates of gastroenteropancreatic neuroendocrine tumors: A large population-based study. Cancer Med. 2018;7:3521-3533. [PMID: 29873204 DOI: 10.1002/cam4.1598] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
21 Cai B, Broder MS, Chang E, Yan T, Metz DC. Predictive factors associated with carcinoid syndrome in patients with gastrointestinal neuroendocrine tumors. World J Gastroenterol 2017; 23(40): 7283-7291 [PMID: 29142475 DOI: 10.3748/wjg.v23.i40.7283] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
22 Li C, Huang J, Yang X, Xia J, Xu G, Zheng H. A primary neuroendocrine tumor of the left ventricle presenting with diarrhea-an unusual experience and literature review. Diagn Pathol 2020;15:32. [PMID: 32245475 DOI: 10.1186/s13000-020-00935-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Shen C, Dasari A, Chu Y, Halperin DM, Zhou S, Xu Y, Shih YT, Yao JC. Clinical, pathological, and demographic factors associated with development of recurrences after surgical resection in elderly patients with neuroendocrine tumors. Ann Oncol 2017;28:1582-9. [PMID: 28444105 DOI: 10.1093/annonc/mdx164] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
24 Gordon E, Chan DL, Arena J, Bernard E, Carr-Boyd E, Clarke SJ, Itchins M, Learoyd D, Sandanayake N, Pavlakis N. Life-threatening diarrhea in neuroendocrine tumors: two case reports. J Med Case Rep 2021;15:542. [PMID: 34706762 DOI: 10.1186/s13256-021-03096-7] [Reference Citation Analysis]
25 Shen C, Dasari A, Xu Y, Zhou S, Gu D, Chu Y, Halperin DM, Shih YT, Yao JC. Pre-existing Symptoms and Healthcare Utilization Prior to Diagnosis of Neuroendocrine Tumors: A SEER-Medicare Database Study. Sci Rep 2018;8:16863. [PMID: 30442902 DOI: 10.1038/s41598-018-35340-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
26 Ito T, Lee L, Jensen RT. Carcinoid-syndrome: recent advances, current status and controversies. Curr Opin Endocrinol Diabetes Obes 2018;25:22-35. [PMID: 29120923 DOI: 10.1097/MED.0000000000000376] [Cited by in Crossref: 37] [Cited by in F6Publishing: 16] [Article Influence: 18.5] [Reference Citation Analysis]
27 Klink AJ, Feinberg B, Yu HT, Ray D, Pulgar S, Phan A, Vinik A. Patterns of Care Among Real-World Patients with Metastatic Neuroendocrine Tumors. Oncologist 2019;24:1331-9. [PMID: 31015313 DOI: 10.1634/theoncologist.2018-0798] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
28 Naraev BG, Halland M, Halperin DM, Purvis AJ, OʼDorisio TM, Halfdanarson TR. Management of Diarrhea in Patients With Carcinoid Syndrome. Pancreas 2019;48:961-72. [PMID: 31425482 DOI: 10.1097/MPA.0000000000001384] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 12.0] [Reference Citation Analysis]
29 Custodio A, Jimenez-Fonseca P, Carmona-Bayonas A, Gomez MJ, Del Olmo-García MI, Lorenzo I, Díaz JÁ, Canal N, De la Cruz G, Villabona C. Use of healthcare REsources and associated COsts in controlled versus uncontrolled carcinoid SYndrome in patients with neuroendocrine tumours: the RECOSY study. Clin Transl Oncol 2021;23:2046-56. [PMID: 34109562 DOI: 10.1007/s12094-021-02608-7] [Reference Citation Analysis]
30 Saavedra C, Barriuso J, McNamara MG, Valle JW, Lamarca A. Spotlight on telotristat ethyl for the treatment of carcinoid syndrome diarrhea: patient selection and reported outcomes. Cancer Manag Res 2019;11:7537-56. [PMID: 31496810 DOI: 10.2147/CMAR.S181439] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
31 Forero Molina MA, Garcia E, Gonzalez-Devia D, García-Duperly R, Vera A. A 17-year-old male with a Small Bowel Neuroendocrine Tumor: flushing differential diagnosis. World Allergy Organ J 2017;10:30. [PMID: 28904734 DOI: 10.1186/s40413-017-0161-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
32 Gosain R, Mukherjee S, Yendamuri SS, Iyer R. Management of Typical and Atypical Pulmonary Carcinoids Based on Different Established Guidelines. Cancers (Basel) 2018;10:E510. [PMID: 30545054 DOI: 10.3390/cancers10120510] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
33 Oleinikov K, Avniel-Polak S, Gross DJ, Grozinsky-Glasberg S. Carcinoid Syndrome: Updates and Review of Current Therapy. Curr Treat Options Oncol 2019;20:70. [PMID: 31286272 DOI: 10.1007/s11864-019-0671-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
34 Li J, Lin Y, Wang Y, Lin H, Lin F, Zhuang Q, Lin X, Wu J. Prognostic nomogram based on the metastatic lymph node ratio for gastric neuroendocrine tumour: SEER database analysis. ESMO Open 2020;5:e000632. [PMID: 32253246 DOI: 10.1136/esmoopen-2019-000632] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
35 Strosberg J, Joish VN, Giacalone S, Perez-Olle R, Fish-Steagall A, Kapoor K, Dharba S, Lapuerta P, Benson AB. TELEPRO: Patient-Reported Carcinoid Syndrome Symptom Improvement Following Initiation of Telotristat Ethyl in the Real World. Oncologist 2019;24:1446-52. [PMID: 31189618 DOI: 10.1634/theoncologist.2018-0921] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
36 Rindi G, Wiedenmann B. Neuroendocrine neoplasia of the gastrointestinal tract revisited: towards precision medicine. Nat Rev Endocrinol 2020;16:590-607. [PMID: 32839579 DOI: 10.1038/s41574-020-0391-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 12.0] [Reference Citation Analysis]
37 Khan MS, Walter T, Buchanan-Hughes A, Worthington E, Keeber L, Feuilly M, Grande E. Differential diagnosis of diarrhoea in patients with neuroendocrine tumours: A systematic review. World J Gastroenterol 2020; 26(30): 4537-4556 [PMID: 32874063 DOI: 10.3748/wjg.v26.i30.4537] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
38 Hendifar AE, Dhall D, Strosberg JR. The Evolving Treatment Algorithm for Advanced Neuroendocrine Neoplasms: Diversity and Commonalities Across Tumor Types. Oncologist 2019;24:54-61. [PMID: 30104288 DOI: 10.1634/theoncologist.2018-0187] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
39 Calanchini M, Tadman M, Krogh J, Fabbri A, Grossman A, Shine B. Measurement of urinary 5-HIAA: correlation between spot versus 24-h urine collection. Endocr Connect 2019;8:1082-8. [PMID: 31265996 DOI: 10.1530/EC-19-0269] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
40 Hofland J, Kaltsas G, de Herder WW. Advances in the Diagnosis and Management of Well-Differentiated Neuroendocrine Neoplasms. Endocr Rev. 2020;41. [PMID: 31555796 DOI: 10.1210/endrev/bnz004] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 28.0] [Reference Citation Analysis]
41 Clement D, Ramage J, Srirajaskanthan R. Update on Pathophysiology, Treatment, and Complications of Carcinoid Syndrome. J Oncol 2020;2020:8341426. [PMID: 32322270 DOI: 10.1155/2020/8341426] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
42 Molina-Cerrillo J, Grande E, Alonso-Gordoa T. Inhibition of Serotonin Synthesis May Have Antitumor Activity? Long-Term Efficacy in a Patient with Gastrointestinal Neuroendocrine Tumor. Oncologist 2019;24:e597-9. [PMID: 30877189 DOI: 10.1634/theoncologist.2018-0776] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
43 Jin XF, Spampatti MP, Spitzweg C, Auernhammer CJ. Supportive therapy in gastroenteropancreatic neuroendocrine tumors: Often forgotten but important. Rev Endocr Metab Disord 2018;19:145-58. [PMID: 29464446 DOI: 10.1007/s11154-018-9443-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
44 Spada F, Rossi RE, Kara E, Laffi A, Massironi S, Rubino M, Grimaldi F, Bhoori S, Fazio N. Carcinoid Syndrome and Hyperinsulinemic Hypoglycemia Associated with Neuroendocrine Neoplasms: A Critical Review on Clinical and Pharmacological Management. Pharmaceuticals (Basel) 2021;14:539. [PMID: 34199977 DOI: 10.3390/ph14060539] [Reference Citation Analysis]
45 Peri M, Fazio N. Clinical Evaluation of Everolimus in the Treatment of Neuroendocrine Tumors of the Lung: Patient Selection and Special Considerations. A Systematic and Critical Review of the Literature. Lung Cancer (Auckl) 2020;11:41-52. [PMID: 32753993 DOI: 10.2147/LCTT.S249928] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Rubin de Celis Ferrari AC, Glasberg J, Riechelmann RP. Carcinoid syndrome: update on the pathophysiology and treatment. Clinics (Sao Paulo). 2018;73:e490s. [PMID: 30133565 DOI: 10.6061/clinics/2018/e490s] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
47 Clement DS, Tesselaar ME, van Leerdam ME, Srirajaskanthan R, Ramage JK. Nutritional and vitamin status in patients with neuroendocrine neoplasms. World J Gastroenterol 2019; 25(10): 1171-1184 [PMID: 30886501 DOI: 10.3748/wjg.v25.i10.1171] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
48 Oleinikov K, Korach A, Planer D, Gilon D, Grozinsky-Glasberg S. Update in carcinoid heart disease - the heart of the matter. Rev Endocr Metab Disord 2021;22:553-61. [PMID: 33443717 DOI: 10.1007/s11154-020-09624-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Contractor T, Harris CR. Loss of copy of MIR1-2 increases CDK4 expression in ileal neuroendocrine tumors. Oncogenesis 2020;9:37. [PMID: 32198354 DOI: 10.1038/s41389-020-0221-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Dillon JS, Chandrasekharan C. Telotristat ethyl: a novel agent for the therapy of carcinoid syndrome diarrhea. Future Oncol 2018;14:1155-64. [PMID: 29350062 DOI: 10.2217/fon-2017-0340] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
51 Koenig A, Krug S, Mueller D, Barth PJ, Koenig U, Scharf M, Ellenrieder V, Michl P, Moll R, Homayunfar K, Kann PH, Stroebel P, Gress TM, Rinke A. Clinicopathological hallmarks and biomarkers of colorectal neuroendocrine neoplasms. PLoS One 2017;12:e0188876. [PMID: 29232390 DOI: 10.1371/journal.pone.0188876] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
52 Lau SC, Abdel-Rahman O, Cheung WY. Improved survival with higher doses of octreotide long-acting release in gastroenteropancreatic neuroendocrine tumors. Med Oncol 2018;35:123. [PMID: 30078166 DOI: 10.1007/s12032-018-1189-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
53 Shen C, Chu Y, Halperin DM, Dasari A, Zhou S, Xu Y, Yao JC, Shih YT. Carcinoid Syndrome and Costs of Care During the First Year After Diagnosis of Neuroendocrine Tumors Among Elderly Patients. Oncologist. 2017;22:1451-1462. [PMID: 28642335 DOI: 10.1634/theoncologist.2017-0149] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
54 Bian D, Qi M, Hu J, Ning Y, Zhou F, Fei K, Zhang P. The comparison of predictive factors regarding prognoses and invasion of thymic neuroendocrine tumors preoperatively and postoperatively. J Thorac Dis 2018;10:1657-69. [PMID: 29707318 DOI: 10.21037/jtd.2018.02.82] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
55 Tian FX, Cai YQ, Zhuang LP, Chen MF, Xiu ZB, Zhang Y, Liu H, Liu ZH, Liu GP, Zeng C, Lin FL, Liu J, Huang ST, Zhang LZ, Lin HY. Clinicopathological features and prognosis of patients with gastric neuroendocrine tumors: A population-based study. Cancer Med. 2018;7:5359-5369. [PMID: 30311450 DOI: 10.1002/cam4.1683] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
56 Ptasnuka M, Ozolins A, Narbuts Z, Truskovs A, Sperga M, Plaudis H. Epidemiological Data and Treatment of Gastroenteropancreatic Neuroendocrine Neoplasms: Insights From Tertiary Referral Hospitals in Latvia. World J Surg 2020;44:585-93. [PMID: 31605174 DOI: 10.1007/s00268-019-05219-0] [Reference Citation Analysis]
57 Anthony LB, Kulke MH, Caplin ME, Bergsland E, Öberg K, Pavel M, Hörsch D, Warner RRP, O'Dorisio TM, Dillon JS, Lapuerta P, Kassler-Taub K, Jiang W. Long-Term Safety Experience with Telotristat Ethyl Across Five Clinical Studies in Patients with Carcinoid Syndrome. Oncologist 2019;24:e662-70. [PMID: 30651397 DOI: 10.1634/theoncologist.2018-0236] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
58 Soyano AE, Kassi M, Kasi PM. Neuroendocrine Tumor Involving the Epicardium. Case Rep Oncol 2017;10:1144-9. [PMID: 29430241 DOI: 10.1159/000485560] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
59 Fernandez CJ, Agarwal M, Pottakkat B, Haroon NN, George AS, Pappachan JM. Gastroenteropancreatic neuroendocrine neoplasms: A clinical snapshot. World J Gastrointest Surg 2021; 13(3): 231-255 [PMID: 33796213 DOI: 10.4240/wjgs.v13.i3.231] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
60 Mohammad Shehata I, Elhassan A, Alejandro Munoz D, Okereke B, Cornett EM, Varrassi G, Imani F, Kaye AD, Sehat-Kashani S, Urits I, Viswanath O. Intraoperative Hypotension Increased Risk in the Oncological Patient. Anesth Pain Med 2021;11:e112830. [PMID: 34221948 DOI: 10.5812/aapm.112830] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
61 Deguelte S, Perrier M, Hammoutene C, Cadiot G, Kianmanesh R. Surgery and Perioperative Management in Small Intestinal Neuroendocrine Tumors. J Clin Med. 2020;9. [PMID: 32708330 DOI: 10.3390/jcm9072319] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
62 Becker A, Schalin-Jäntti C, Itkonen O. Comparison of Serum and Urinary 5-Hydroxyindoleacetic Acid as Biomarker for Neuroendocrine Neoplasms. J Endocr Soc 2021;5:bvab106. [PMID: 34195530 DOI: 10.1210/jendso/bvab106] [Reference Citation Analysis]
63 Shogbesan O, Abdulkareem A, Pappachen B, Altomare J. Primary Mesenteric Carcinoid Tumor Presenting with Carcinoid Syndrome. Case Rep Gastroenterol 2018;12:396-401. [PMID: 30186091 DOI: 10.1159/000490522] [Reference Citation Analysis]
64 Chan DL, Singh S. Developments in the treatment of carcinoid syndrome - impact of telotristat. Ther Clin Risk Manag 2018;14:323-9. [PMID: 29503551 DOI: 10.2147/TCRM.S126143] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
65 Stueven AK, Kayser A, Wetz C, Amthauer H, Wree A, Tacke F, Wiedenmann B, Roderburg C, Jann H. Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future. Int J Mol Sci 2019;20:E3049. [PMID: 31234481 DOI: 10.3390/ijms20123049] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 14.0] [Reference Citation Analysis]
66 Fisher GA Jr, Wolin EM, Liyanage N, Pitman Lowenthal S, Mirakhur B, Pommier RF, Shaheen M, Vinik A; ELECT Study Group. Patient-Reported Symptom Control of Diarrhea and Flushing in Patients with Neuroendocrine Tumors Treated with Lanreotide Depot/Autogel: Results from a Randomized, Placebo-Controlled, Double-Blind and 32-Week Open-Label Study. Oncologist 2018;23:16-24. [PMID: 29038234 DOI: 10.1634/theoncologist.2017-0284] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
67 Halperin DM, Huynh L, Beaumont JL, Cai B, Bhak RH, Narkhede S, Totev T, Duh MS, Neary MP, Cella D. Assessment of change in quality of life, carcinoid syndrome symptoms and healthcare resource utilization in patients with carcinoid syndrome. BMC Cancer 2019;19:274. [PMID: 30922252 DOI: 10.1186/s12885-019-5459-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
68 Pavel M, Gross DJ, Benavent M, Perros P, Srirajaskanthan R, Warner RRP, Kulke MH, Anthony LB, Kunz PL, Hörsch D, Weickert MO, Lapuerta P, Jiang W, Kassler-Taub K, Wason S, Fleming R, Fleming D, Garcia-Carbonero R. Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial. Endocr Relat Cancer 2018;25:309-22. [PMID: 29330194 DOI: 10.1530/ERC-17-0455] [Cited by in Crossref: 58] [Cited by in F6Publishing: 23] [Article Influence: 19.3] [Reference Citation Analysis]